Psoriasis valgaris, Generalized pustular psoriasis, Erythrodermic psoriasis
Conditions
Sponsors
Eli Lilly Japan K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Participant must have chronic plaque psoriasis for at least 6 months.
Exclusion criteria
Exclusion criteria: -Participant must not be breastfeeding or nursing woman. -Participant must not have had serious, opportunistic, or chronic/recurring infection within 3 months. -Participant must not have received a Bacillus Calmette-Guerin (BCG) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study. -Participant must not have any other skin conditions (excluding psoriasis). -Participant must not have previous exposure to Cosentyx and any other biologic therapy targeting IL-17 (including Taltz). -Participant must not have received anti-tumor necrosis factor (TNF) biologics within 8 weeks. -Participant must not have previous exposure to any biologic therapy targeting IL-23 (including Stelara).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy sPGA and PASI | — |
Secondary
| Measure | Time frame |
|---|---|
| efficacy pharmacokinetics PASI etc., PK parameters | — |
Countries
Asia except Japan, Europe, Japan, North America, Oceania, South America
Outcome results
None listed